88 related articles for article (PubMed ID: 29058787)
1. Drug repurposing: An approach to tackle drug resistance in S. typhimurium.
Balasundaram P; Veerappapillai S; Krishnamurthy S; Karuppasamy R
J Cell Biochem; 2018 Mar; 119(3):2818-2831. PubMed ID: 29058787
[TBL] [Abstract][Full Text] [Related]
2. Identification of Potential Therapeutics to Conquer Drug Resistance in Salmonella typhimurium: Drug Repurposing Strategy.
Preethi B; Shanthi V; Ramanathan K
BioDrugs; 2016 Dec; 30(6):593-605. PubMed ID: 27761807
[TBL] [Abstract][Full Text] [Related]
3. Characterization of Salmonella Typhimurium DNA gyrase as a target of quinolones.
Kongsoi S; Yokoyama K; Suprasert A; Utrarachkij F; Nakajima C; Suthienkul O; Suzuki Y
Drug Test Anal; 2015 Aug; 7(8):714-20. PubMed ID: 25381884
[TBL] [Abstract][Full Text] [Related]
4. Molecular level understanding of resistance to nalidixic acid in Salmonella enteric serovar typhimurium associates with the S83F sequence type.
Preethi B; Ramanathan K
Eur Biophys J; 2016 Jan; 45(1):35-44. PubMed ID: 26329667
[TBL] [Abstract][Full Text] [Related]
5. Amino acid substitutions in GyrA affect quinolone susceptibility in Salmonella typhimurium.
Kongsoi S; Changkwanyeun R; Yokoyama K; Nakajima C; Changkaew K; Suthienkul O; Suzuki Y
Drug Test Anal; 2016 Oct; 8(10):1065-1070. PubMed ID: 26514939
[TBL] [Abstract][Full Text] [Related]
6. Investigation of Nalidixic Acid Resistance Mechanism in Salmonella enterica Using Molecular Simulation Techniques.
Preethi B; Shanthi V; Ramanathan K
Appl Biochem Biotechnol; 2015 Sep; 177(2):528-40. PubMed ID: 26208690
[TBL] [Abstract][Full Text] [Related]
7. Interaction of nalidixic acid and ciprofloxacin with wild type and mutated quinolone-resistance-determining region of DNA gyrase A.
Vashist J; Vishvanath ; Kapoor R; Kapil A; Yennamalli R; Subbarao N; Rajeswari MR
Indian J Biochem Biophys; 2009 Apr; 46(2):147-53. PubMed ID: 19517991
[TBL] [Abstract][Full Text] [Related]
8. Antibacterial Evaluation and Virtual Screening of New Thiazolyl-Triazole Schiff Bases as Potential DNA-Gyrase Inhibitors.
Nastasă C; Vodnar DC; Ionuţ I; Stana A; Benedec D; Tamaian R; Oniga O; Tiperciuc B
Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29324679
[TBL] [Abstract][Full Text] [Related]
9. Analysis of the mechanism of quinolone resistance in nalidixic acid-resistant clinical isolates of Salmonella serotype Typhimurium.
Ruiz J; Castro D; Goñi P; Santamaria JA; Borrego JJ; Vila J
J Med Microbiol; 1997 Jul; 46(7):623-8. PubMed ID: 9236748
[TBL] [Abstract][Full Text] [Related]
10. The role of ATP pools in persister cell formation in (fluoro)quinolone-susceptible and -resistant strains of Salmonella enterica ser. Typhimurium.
Braetz S; Schwerk P; Thompson A; Tedin K; Fulde M
Vet Microbiol; 2017 Oct; 210():116-123. PubMed ID: 29103680
[TBL] [Abstract][Full Text] [Related]
11. Molecular Dynamics Simulations of Quinolone Resistance-Associated T86I and P104S Mutations in Campylobacter jejuni gyrA: Unraveling Structural Repercussions.
Mehla K; Ramana J
Microb Drug Resist; 2018 Apr; 24(3):232-243. PubMed ID: 28759328
[TBL] [Abstract][Full Text] [Related]
12. Pharmacophore generation, atom-based 3D-QSAR and molecular dynamics simulation analyses of pyridine-3-carboxamide-6-yl-urea analogues as potential gyrase B inhibitors.
Azam MA; Thathan J
SAR QSAR Environ Res; 2017 Apr; 28(4):275-296. PubMed ID: 28399673
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of plasmid-mediated quinolone resistance and mutations in the gyrase and topoisomerase IV genes in Salmonella isolated from 12 tertiary-care hospitals in Korea.
Jeong HS; Kim JA; Shin JH; Chang CL; Jeong J; Cho JH; Kim MN; Kim S; Kim YR; Lee CH; Lee K; Lee MA; Lee WG; Shin JH; Lee JN
Microb Drug Resist; 2011 Dec; 17(4):551-7. PubMed ID: 21830947
[TBL] [Abstract][Full Text] [Related]
14. Impact of mutations in DNA gyrase genes on quinolone resistance in Campylobacter jejuni.
Changkwanyeun R; Yamaguchi T; Kongsoi S; Changkaew K; Yokoyama K; Kim H; Suthienkul O; Usui M; Tamura Y; Nakajima C; Suzuki Y
Drug Test Anal; 2016 Oct; 8(10):1071-1076. PubMed ID: 26857529
[TBL] [Abstract][Full Text] [Related]
15. Discovery of novel DNA gyrase inhibitors by high-throughput virtual screening.
Ostrov DA; Hernández Prada JA; Corsino PE; Finton KA; Le N; Rowe TC
Antimicrob Agents Chemother; 2007 Oct; 51(10):3688-98. PubMed ID: 17682095
[TBL] [Abstract][Full Text] [Related]
16. Dual inhibition of Staphylococcus aureus DNA gyrase and topoisomerase IV activity by phenylalanine-derived (Z)-5-arylmethylidene rhodanines.
Werner MM; Patel BA; Talele TT; Ashby CR; Li Z; Zauhar RJ
Bioorg Med Chem; 2015 Sep; 23(18):6125-37. PubMed ID: 26320664
[TBL] [Abstract][Full Text] [Related]
17. Fragment-based discovery of DNA gyrase inhibitors targeting the ATPase subunit of GyrB.
Mesleh MF; Cross JB; Zhang J; Kahmann J; Andersen OA; Barker J; Cheng RK; Felicetti B; Wood M; Hadfield AT; Scheich C; Moy TI; Yang Q; Shotwell J; Nguyen K; Lippa B; Dolle R; Ryan MD
Bioorg Med Chem Lett; 2016 Feb; 26(4):1314-8. PubMed ID: 26786695
[TBL] [Abstract][Full Text] [Related]
18. Characterization of Campylobacter jejuni DNA gyrase as the target of quinolones.
Changkwanyeun R; Usui M; Kongsoi S; Yokoyama K; Kim H; Suthienkul O; Changkaew K; Nakajima C; Tamura Y; Suzuki Y
J Infect Chemother; 2015 Aug; 21(8):604-9. PubMed ID: 26096494
[TBL] [Abstract][Full Text] [Related]
19. De novo design of novel DNA-gyrase inhibitors based on 2D molecular fingerprints.
Huang Z; Lin K; You Q
Bioorg Med Chem Lett; 2013 Jul; 23(14):4166-71. PubMed ID: 23743285
[TBL] [Abstract][Full Text] [Related]
20. Role of the extended alpha4 domain of Staphylococcus aureus gyrase A protein in determining low sensitivity to quinolones.
Strahilevitz J; Robicsek A; Hooper DC
Antimicrob Agents Chemother; 2006 Feb; 50(2):600-6. PubMed ID: 16436716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
